The development-of oxygen-carrying blood substitutes has progressed si
gnificantly in the last decade with phase I and phase II clinical tria
ls of both hemoglobin-based and perfluorocarbon-based oxygen carriers
nearing completion. As these products approach clinical use it is impo
rtant for the laboratory medicine community to be aware of their effec
ts on routine laboratory testing and the settings in which they might
be used. Here we review the forces driving the development of oxygen-c
arrying blood substitutes, the clinical settings in which they might b
e used, the major categories of oxygen carriers in clinical trials, an
d the challenges faced by these products as they approach clinical use
.